by Katy Spink, Ph.D., Dark Horse Consulting Group’s COO & MP Katy Spink Presents at an Internal DHC Retreat in 2018 Full disclosure: my CGT career began just over 20 years ago when I worked with pluripotent stem cells at Geron . I’ve always been a believer in the...
by Dr. Steve Oh, PhD Independent Cell Therapy Leader Singapore A webinar presented by the ISCT Process Development and Manufacturing (PDM) Committee Particulates are everywhere but do they pose a problem in cell and gene therapy products? On the 16 Oct. the...
ISCT’s Process Development & Manufacturing Committee invites you to take part in a survey to determine the current state of Process Analytical Technologies (PAT) in Cell & Gene Therapy (C>) Manufacturing. Fundamental analytical challenges exist when manipulating and expanding...
Sponsored content provided by Stemcell Technologies ISCT Industry Member Human pluripotent stem cells (hPSCs) can be a powerful tool in your cell and gene therapy development toolkit. However, most clinical applications require many more hPSCs than can be generated in a...
William Watt, PhD President, Astellas Venture Management LLC Please introduce yourself. What is your background and experience in cell and gene therapy? My basic training was as a scientist, I earned a PhD in Pharmacology from the University of Washington and carried out 3...
by Shannon Eaker, PhD, Chief Technology Officer at Xcell Biosciences * Dominic Clarke, PhD, Consultant & Chief Strategy Officer at Orange County Bio * *Representing the International Society for Cell & Gene Therapy (ISCT) Process Development and Manufacturing (PDM)...
Miltenyi Bioindustry is a global CDMO service provider specializing in cell and gene therapy. With more than 25 years of experience, we offer comprehensive process development and manufacturing services for both autologous and allogeneic cell therapy programs. We provide high-quality lentiviral...
Proprietary Platform Moves Promising Cell Therapy Candidates from Contract to Clinic in Six Months NEWARK, NJ, June 1, 2023 – BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP Advanced Therapy...
Monday, January 9, 2023 (Toronto, ON) – Viral vectors are critical components in the manufacturing of cell and gene therapies, but their production is currently a key bottleneck and cost driver. CCRM, a leader in developing and commercializing cell and gene therapies, has partnered with Membio,...
Recently, Eutilex, a partner of GenScript ProBio, announced MFDS clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations on this. 2 years ago, GenScript ProBio and Eutilex announced that the parties...